Valuation: Janux Therapeutics, Inc.

Market Cap 979M 859M 796M 732M 1.38B 94.18B 1.4B 9.49B 3.71B 46.15B 3.67B 3.6B 160B P/E 2026 *
-9.58x
P/E 2027 * -6.09x
Enterprise Value 106M 92.68M 85.88M 78.99M 149M 10.17B 151M 1.02B 401M 4.98B 397M 388M 17.24B EV / Sales 2026 *
3.34x
EV / Sales 2027 * 34.8x
Free-Float
98.3%
Yield 2026 *
-
Yield 2027 * -
1 day+1.31%
1 week+0.74%
Current month+5.86%
1 month+14.35%
3 months+2.46%
6 months+23.65%
Current year+17.83%
1 week 15.5
Extreme 15.5
16.53
1 month 14.16
Extreme 14.16
16.9
Current year 12.12
Extreme 12.12
16.9
1 year 12.12
Extreme 12.12
35.34
3 years 5.65
Extreme 5.65
71.71
5 years 5.65
Extreme 5.65
71.71
10 years 5.65
Extreme 5.65
71.71
Manager TitleAgeSince
Chief Executive Officer 67 31/05/2017
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 57 31/12/2020
Director TitleAgeSince
Director/Board Member 64 17/03/2021
Director/Board Member 55 17/03/2021
Director/Board Member 40 28/02/2021
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Fiscal year

Founder

14,000 0.0233%
11/06/26
RA Capital Management LP
FreeCompany 21,000 0.0349%
11/06/26 Free

Director

21,000 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
+1.31%+0.74%-38.41%+30.39% 979M
+0.88%+0.08%+54.51%+58.77% 53.79B
+1.80%+5.16%+53.09%+86.95% 54.69B
+1.50%-0.48%+5.91%+410.19% 23.2B
+0.18%+2.51%-16.08%-14.29% 23.31B
+1.46%+4.02%+35.97%-4.03% 20.03B
+0.30%-2.68%+30.50%-33.10% 17.31B
0.00%-6.00%+163.95%+284.69% 14.99B
+1.49%+1.49%+31.63%+654.98% 15.36B
+1.06%+0.14%+26.20%+182.44% 13.96B
Average +1.00%-1.72%+34.73%+165.70% 23.76B
Weighted average by Cap. +1.09%-1.78%+42.58%+140.37%

Financials

2026 *2027 *
Net sales 31.59M 27.72M 25.68M 23.62M 44.57M 3.04B 45.15M 306M 120M 1.49B 119M 116M 5.16B 6.95M 6.1M 5.65M 5.2M 9.81M 669M 9.93M 67.41M 26.37M 328M 26.1M 25.53M 1.13B
Net income -104M -91.21M -84.51M -77.74M -147M -10B -149M -1.01B -394M -4.9B -390M -382M -16.97B -178M -156M -145M -133M -251M -17.11B -254M -1.72B -674M -8.38B -667M -653M -29.02B
Net Debt -873M -766M -710M -653M -1.23B -84.02B -1.25B -8.47B -3.31B -41.17B -3.28B -3.21B -142B -737M -647M -599M -551M -1.04B -70.92B -1.05B -7.15B -2.8B -34.75B -2.77B -2.71B -120B
Logo Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.
Employees
108
Date Price Change Volume
21/07/26 US$16.26 +1.31% 710,894
20/07/26 US$16.05 -1.29% 805,001
17/07/26 US$16.26 +2.65% 805,838
16/07/26 US$15.84 -1.19% 648,090
15/07/26 US$16.03 +1.58% 846,651
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
16.05USD
Average target price
37.19USD
Spread / Average Target
+131.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JANX Stock